Clinical Trial: Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469241) titled 'Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.' on Feb. 24.

Brief Summary: FUTURE-3 was a prospective, multicenter, single-arm phase II study designed to explore the efficacy and safety of MRI-guided individualized chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. The primary endpoint was one-year progression-free survival rate.

Study Start Date: March 10

Study Type: INTERVENTIONAL

Condition: Advanced Esophageal Squamous Cell Carcinoma Unresectable Esophageal Squamous Cell Carcinoma

Intervention: COMBINATION_PRODUCT: Concurrent chem...